Small

Zacks Small Cap Analysis – SYRA: New Enterprise Exercise Sturdy; SYRA Guides to 64%-100% ‘24E Income Development – Model Slux

by
Zacks Small Cap Analysis – SYRA: New Enterprise Exercise Sturdy; SYRA Guides to 64%-100% ‘24E Income Development – Model Slux

By M. Marin NASDAQ:SYRA READ THE FULL SYRA RESEARCH REPORT Key takeaways 2023 outcomes, 2024 steerage… Syra Well being Corp. (NASDAQ:SYRA), is a healthcare know-how firm creating end-to-end options in behavioral and psychological well being, digital well being, inhabitants well being, well being schooling providers, administration and healthcare workforce and authorities providers, reported 2023 outcomes … Read more

Zacks Small Cap Analysis – REVB Begins Trials with Good Money on Hand – Model Slux

by

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVBRESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences firm targeted on the event of immunologic-based therapies for the prevention and therapy of illness. Revelation has a number of product candidates in growth that we consider have promising potential and are primarily based on the biology of … Read more

Getting Licensed – Cyber Safety Decisions for Small Companies – Model Slux

by
Getting Licensed – Cyber Safety Decisions for Small Companies – Model Slux

When you had the selection of spending cash with a enterprise that’s accredited to maintain your knowledge protected, or one which lacks primary safety controls, you’re at all times going to go together with the extra reliable choice. That is the place having a badge highlighting your Cyber Necessities qualification might help as a result … Read more

Zacks Small Cap Analysis – RANI: 2023 Outcomes – Model Slux

by
Zacks Small Cap Analysis – RANI: 2023 Outcomes – Model Slux

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) started 2024 with topline outcomes from its Part I examine of RT-111, or ustekinumab, delivering the biologic with its ingestible robotic RaniPill (RP). Bioavailability of 84% relative to subcutaneous injection was achieved within the examine and the RT-111 was … Read more

Zacks Small Cap Analysis – PBSV Releases Quarterly Outcomes – Model Slux

by

By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) introduced outcomes for the quarter ended January 31, 2024. The headline was beneath expectations and administration famous that the corporate was “challenged” within the quarter. Administration didn’t elaborate on what these challenges had been, however all geographical segments of the corporate’s … Read more

x